All In Biotech

Drug Trial Radar · NCT01908829

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms

Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,174 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,174

Actual

Start

Jul 10, 2013

Primary completion

Nov 24, 2014

Study completion Nov 25, 2014

Sponsor

Lead sponsor
Astellas Pharma Europe Ltd.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jul 26, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence than when using the antimuscarinic treatment alone.

Conditions

  • Urinary Bladder Diseases
  • Urinary Bladder Overactive
  • Urologic Diseases

Interventions

  • mirabegron 25 mgDrug

    Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.

  • mirabegron 50 mgDrug

    Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.

  • solifenacin 5 mgDrug

    Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.

  • solifenacin 10 mgDrug

    Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.

  • mirabegron 25 mg matching placeboDrug

    Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

  • mirabegron 50 mg matching placeboDrug

    Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

  • solifenacin 5 mg matching placeboDrug

    Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

  • solifenacin 10 mg matching placeboDrug

    Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 HoursTime frame: Baseline and end of treatment (up to 12 weeks)

Locations

219 sites in 31 countries. Site status is shown where the registry gives one.

  • Genova Clinical Research

    Tucson, Arizona

  • Associated Pharmaceutical Research Center, Inc.

    Buena Park, California

  • The American Institute of Research

    Los Angeles, California

  • Bayview Research Group

    Valley Village, California

  • Meridien Research

    Brooksville, Florida

  • Innovative Research of West FL

    Clearwater, Florida

  • Best Quality Research Inc.

    Hialeah, Florida

  • Palmetto Professional Research

    Hialeah, Florida

  • Urology Center of Central Florida

    Kissimmee, Florida

  • Meridien Research

    Tampa, Florida

  • Stedman Clinical Trials

    Tampa, Florida

  • Private Practice

    West Palm Beach, Florida

  • Meridian Clinical Research, LLC

    Savannah, Georgia

  • Herman Clinical Research

    Suwanee, Georgia

  • North Idaho Urology

    Coeur d'Alene, Idaho

  • First Urology, PSC

    Jeffersonville, Indiana

  • Deaconess Gateway Health Center

    Newburgh, Indiana

  • MedStar Health Research Institute

    Hyattsville, Maryland

  • Bay State Clinical Trials, Inc.

    Watertown, Massachusetts

  • Beyer Research

    Kalamazoo, Michigan

  • Quality Clinical Research

    Omaha, Nebraska

  • Albuquerque Clinical Trials, Inc.

    Albuquerque, New Mexico

  • Brooklyn Urology Research Group

    Brooklyn, New York

  • Advanced Urology Centers of New York

    Garden City, New York

  • Premier Medical Group of the Hudson Valley PC

    Kingston, New York

  • Premier Medical Group of the Hudson Valley PC

    Poughkeepsie, New York

  • PMG Research of Raleigh, dba PMG Research of Cary

    Cary, North Carolina

  • Alliance Urology Specialists

    Greensboro, North Carolina

  • Wake Research Associates LLC

    Raleigh, North Carolina

  • PMG Research of Winston-Salem, LLC

    Winston-Salem, North Carolina

  • The Urology Group

    Cincinnati, Ohio

  • Providence Health Partners

    Dayton, Ohio

  • The Clinical Trial Center

    Jenkintown, Pennsylvania

  • Health Concepts

    Rapid City, South Dakota

  • Jean Brown Research

    Salt Lake City, Utah

  • Alexandria Clinical Research

    Alexandria, Virginia

  • Site: 37402

    Yerevan, Armenia

  • Site: 37403

    Yerevan, Armenia

  • Site: 37405

    Yerevan, Armenia

  • Site: 61006

    Adelaide, Australia

Showing 40 of 219 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.